Peroxisome proliferator-activated receptor agonists modulate neuropathic pain: A link to chemokines?

Frontiers in Cellular Neuroscience

Volumn 8, Issue AUG, 2014, Pages

  Freitag, Caroline M ^a   Miller, Richard J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Fractalkine; MCP 1; MIP 1 ; Neuropathic pain; Peroxisome proliferator activated receptors; RANTES; SDF 1

Indexed keywords

ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; CANNABINOID; CHEMOKINE; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR4; CXCL1 CHEMOKINE; FRACTALKINE; G PROTEIN COUPLED RECEPTOR; INTERLEUKIN 1BETA; LOCAL ANESTHETIC AGENT; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OPIATE; PALMIDROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; RANTES; SEROTONIN UPTAKE INHIBITOR; SODIUM CHANNEL BLOCKING AGENT; STEROID; STROMAL CELL DERIVED FACTOR 1; TRICYCLIC ANTIDEPRESSANT AGENT; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

CD4+ T LYMPHOCYTE; CELL MIGRATION; CHRONIC INFLAMMATION; GENE EXPRESSION; GENE REPRESSION; GENE TRANSLOCATION; GENETIC TRANSCRIPTION; GUILLAIN BARRE SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFLAMMATION; META ANALYSIS (TOPIC); NERVE FIBER; NERVOUS SYSTEM DEVELOPMENT; NEUROPATHIC PAIN; NEUROPROTECTION; NEUROTRANSMITTER RELEASE; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SPINAL CORD INJURY; TUMOR VASCULARIZATION; UPREGULATION;

EID: 84927601397     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2014.00238     Document Type: Review

References (173)

1. Abbadie, C., Lindia, J. A., Cumiskey, A. M., Peterson, L. B., Mudgett, J. S., Bayne, E. K., et al. (2003). Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2. Proc. Natl. Acad. Sci. U S A 100, 7947-7952. doi: 10.1073/pnas.1331358100
2. Arnold, R., and König, W. (2006). Peroxisome-proliferator-activated receptor-gamma agonists inhibit the release of proinflammatory cytokines from RSV-infected epithelial cells. Virology 346, 427-439. doi: 10.1016/j.virol.2005.11.009
3. Barclay, J., Patel, S., Dorn, G., Wotherspoon, G., Moffatt, S., Eunson, L., et al. (2002). Functional downregulation of P2X3 receptor subunit in rat sensory neurons reveals a significant role in chronic neuropathic and inflammatory pain. J. Neurosci. 22, 8139-8147.
4. Barlic, J., and Murphy, P. M. (2007). An oxidized lipid-peroxisome proliferator-activated receptor gamma-chemokine pathway in the regulation of macrophage-vascular smooth muscle cell adhesion. Trends Cardiovasc. Med. 17, 269-274. doi: 10.1016/j.tcm.2007.09.004
5. Bassaganya-Riera, J., Guri, A. J., Lu, P., Climent, M., Carbo, A., Sobral, B. W., et al. (2011). Abscisic acid regulates inflammation via ligand-binding domain-independent activation of peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 286, 2504-2516. doi: 10.1074/jbc.M110.160077
6. Bedi, S. S., Yang, Q., Crook, R. J., Du, J., Wu, Z., Fishman, H. M., et al. (2010). Chronic spontaneous activity generated in the somata of primary nociceptors is associated with pain-related behavior after spinal cord injury. J. Neurosci. 30, 14870-14882. doi: 10.1523/JNEUROSCI.2428-10.2010
7. Benamar, K., Geller, E. B., and Adler, M. W. (2008). Elevated level of the proinflammatory chemokine, RANTES/CCL5, in the periaqueductal grey causes hyperalgesia in rats. Eur. J. Pharmacol. 592, 93-95. doi: 10.1016/j.ejphar.2008.07.009
8. Bhangoo, S., Ren, D., Miller, R. J., Henry, K. J., Lineswala, J., Hamdouchi, C., et al. (2007). Delayed functional expression of neuronal chemokine receptors following focal nerve demyelination in the rat: a mechanism for the development of chronic sensitization of peripheral nociceptors. Mol. Pain 3: 38. doi: 10.1186/1744-8069-3-38
9. Bhangoo, S. K., Ripsch, M. S., Buchanan, D. J., Miller, R. J., and White, F. A. (2009). Increased chemokine signaling in a model of HIV1-associated peripheral neuropathy. Mol. Pain 5: 48. doi: 10.1186/1744-8069-5-48
10. Biasiotta, A., La Cesa, S., Leone, C., Di Stefano, G., Truini, A., and Cruccu, G. (2010). Efficacy of Palmitoylethanolamide in patients with painful neuropathy. A clinical and neurophysiological open study. Preliminary results. Eur. J. Pain Suppl. 4: 77. doi: 10.1016/s1754-3207(10)70270-4
11. Bouhassira, D., Lantéri-Minet, M., Attal, N., Laurent, B., and Touboul, C. (2008). Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 136, 380-387. doi: 10.1016/j.pain.2007.08.013
12. Bursill, C. A., Castro, M. L., Beattie, D. T., Nakhla, S., van der Vorst, E., Heather, A. K., et al. (2010). High-density lipoproteins suppress chemokines and chemokine receptors in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 30, 1773-1778. doi: 10.1161/ATVBAHA.110.211342
13. Calvo, M., Dawes, J. M., and Bennett, D. L. H. (2012). The role of the immune system in the generation of neuropathic pain. Lancet Neurol. 11, 629-642. doi: 10.1016/S1474-4422(12)70134-5
14. Cha, B., Lim, J. W., Kim, K. H., and Kim, H. (2011). 15-deoxy-D12, 14-prostaglandin J2 suppresses RANTES expression by inhibiting NADPH oxidase activation in Helicobacter pylori-infected gastric epithelial cells. J. Physiol. Pharmacol. 62, 167-174.
15. Charo, I. F., and Ransohoff, R. M. (2006). The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354, 610-621. doi: 10.1056/nejmra052723
16. Chen, Y., Green, S. R., Ho, J., Li, A., Almazan, F., and Quehenberger, O. (2005). The mouse CCR2 gene is regulated by two promoters that are responsive to plasma cholesterol and peroxisome proliferator-activated receptor gamma ligands. Biochem. Biophys. Res. Commun. 332, 188-193. doi: 10.1016/j.bbrc.2005.04.110
17. Churi, S. B., Abdel-Aleem, O. S., Tumber, K. K., Scuderi-Porter, H., and Taylor, B. K. (2008). Intrathecal rosiglitazone acts at peroxisome proliferator-activated receptor-gamma to rapidly inhibit neuropathic pain in rats. J. Pain. 9, 639-649. doi: 10.1016/j.jpain.2008.02.002
18. Clark, A. K., Yip, P. K., and Malcangio, M. (2009). The liberation of fractalkine in the dorsal horn requires microglial cathepsin S. J. Neurosci. 29, 6945-6954. doi: 10.1523/JNEUROSCI.0828-09.2009
19. Conti, P., Reale, M., Barbacane, R. C., Felaco, M., Grilli, A., and Theoharides, T. C. (1998). Mast cell recruitment after subcutaneous injection of RANTES in the sole of the rat paw. Br. J. Haematol. 103, 798-803. doi: 10.1046/j.1365-2141.1998.1060.x
20. Costa, B., Comelli, F., Bettoni, I., Colleoni, M., and Giagnoni, G. (2008). The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. Pain 139, 541-550. doi: 10.1016/j.pain.2008.06.003
21. Costigan, M., Scholz, J., and Woolf, C. J. (2009). Neuropathic pain: a maladaptive response of the nervous system to damage. Annu. Rev. Neurosci. 32, 1-32. doi: 10.1146/annurev.neuro.051508.135531
22. Coull, J. A. M., Beggs, S., Boudreau, D., Boivin, D., Tsuda, M., Inoue, K., et al. (2005). BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature 438, 1017-1021. doi: 10.1038/nature04223
23. D'Agostino, G., La Rana, G., Russo, R., Sasso, O., Iacono, A., Esposito, E., et al. (2007). Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous peroxisome proliferator-activated receptor-alpha agonist, modulates carrageenan-induced paw edema in mice. J. Pharmacol. Exp. Ther. 322, 1137-1143. doi: 10.1124/jpet.107.123265
24. D'Agostino, G., La Rana, G., Russo, R., Sasso, O., Iacono, A., Esposito, E., et al. (2009). Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kappaB nuclear signalling in dorsal root ganglia. Eur. J. Pharmacol. 613, 54-59. doi: 10.1016/j.ejphar.2009.04.022
25. Dansereau, M.-A., Gosselin, R.-D., Pohl, M., Pommier, B., Mechighel, P., Mauborgne, A., et al. (2008). Spinal CCL2 pronociceptive action is no longer effective in CCR2 receptor antagonist-treated rats. J. Neurochem. 106, 757-769. doi: 10.1111/j.1471-4159.2008.05429.x
26. Dehmer, T., Heneka, M. T., Sastre, M., Dichgans, J., and Schulz, J. B. (2004). Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J. Neurochem. 88, 494-501. doi: 10.1046/j.1471-4159.2003.02210.x
27. Desio, P. (2010). Associazione tra pregabalin e palmitoiletanolamide (PEA) per il trattamento del dolore neuropatico [Association of palmitoylethanolamide and pregabalin in the management of neuropathic pain]. Pathos 17, 9-14.
28. DeVries, M. E., Kelvin, A. A., Xu, L., Ran, L., Robinson, J., and Kelvin, D. J. (2006). Defining the origins and evolution of the chemokine/chemokine receptor system. J. Immunol. 176, 401-415. doi: 10.4049/jimmunol.176.1.401
29. Di Cesare Mannelli, L., D'Agostino, G., Pacini, A., Russo, R., Zanardelli, M., Ghelardini, C., et al. (2013). Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: pain relief and neuroprotection share a PPAR-alpha-mediated mechanism. Mediators Inflamm. 2013: 328797. doi: 10.1155/2013/328797
30. Drew, P. D., Storer, P. D., Xu, J., and Chavis, J. A. (2005). Hormone regulation of microglial cell activation: relevance to multiple sclerosis. Brain Res. Brain Res. Rev. 48, 322-327. doi: 10.1016/j.brainresrev.2004.12.020
31. Empl, M., Renaud, S., Erne, B., Fuhr, P., Straube, A., Schaeren-Wiemers, N., et al. (2001). TNF-alpha expression in painful and nonpainful neuropathies. Neurology 56, 1371-1377. doi: 10.1212/wnl.56.10.1371
32. Flügel, A., Hager, G., Horvat, A., Spitzer, C., Singer, G. M., Graeber, M. B., et al. (2001). Neuronal MCP-1 expression in response to remote nerve injury. J. Cereb. Blood Flow Metab. 21, 69-76. doi: 10.1097/00004647-200101000-00009
33. Foryst-Ludwig, A., Hartge, M., Clemenz, M., Sprang, C., Hess, K., Marx, N., et al. (2010). PPARgamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice. Cardiovasc. Diabetol. 9: 64. doi: 10.1186/1475-2840-9-64
34. Frisén, J., Risling, M., and Fried, K. (1993). Distribution and axonal relations of macrophages in a neuroma. Neuroscience 55, 1003-1013. doi: 10.1016/0306-4522(93)90314-6
35. Gao, Y.-J., and Ji, R.-R. (2010). Chemokines, neuronal-glial interactions and central processing of neuropathic pain. Pharmacol. Ther. 126, 56-68. doi: 10.1016/j.pharmthera.2010.01.002
36. Genovese, T., Esposito, E., Mazzon, E., Di Paola, R., Meli, R., Bramanti, P., et al. (2008). Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury. J. Pharmacol. Exp. Ther. 326, 12-23. doi: 10.1124/jpet.108.136903
37. Glass, C. K., and Saijo, K. (2010). Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat. Rev. Immunol. 10, 365-376. doi: 10.1038/nri2748
38. Gosset, P., Charbonnier, A. S., Delerive, P., Fontaine, J., Staels, B., Pestel, J., et al. (2001). Peroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived dendritic cells. Eur. J. Immunol. 31, 2857-2865. doi: 10.1002/1521-4141(2001010)31:10<2857::aid-immu2857>3.0.co;2-x
39. Guri, A. J., Hontecillas, R., Ferrer, G., Casagran, O., Wankhade, U., Noble, A. M., et al. (2008). Loss of PPAR gamma in immune cells impairs the ability of abscisic acid to improve insulin sensitivity by suppressing monocyte chemoattractant protein-1 expression and macrophage infiltration into white adipose tissue. J. Nutr. Biochem. 19, 216-228. doi: 10.1016/j.jnutbio.2007.02.010
40. Gurley, C., Nichols, J., Liu, S., Phulwani, N. K., Esen, N., and Kielian, T. (2008). Microglia and astrocyte activation by toll-like receptor ligands: modulation by PPAR-gamma agonists. PPAR Res. 2008: 453120. doi: 10.1155/2008/453120
41. Han, K. H., Ryu, J., Hong, K. H., Ko, J., Pak, Y. K., Kim, J.-B., et al. (2005). HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo. Circulation 111, 1439-1447. doi: 10.1161/01.cir.0000158484.18024.1f
42. Harden, N., and Cohen, M. (2003). Unmet needs in the management of neuropathic pain. J. Pain Symptom Manage. 25, S12-S17. doi: 10.1016/s0885-3924(03)00065-4
43. Hasegawa-Moriyama, M., Kurimoto, T., Nakama, M., Godai, K., Kojima, M., Kuwaki, T., et al. (2013). Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone attenuates inflammatory pain through the induction of heme oxygenase-1 in macrophages. Pain 154, 1402-1412. doi: 10.1016/j.pain.2013.04.039
44. Hasegawa-Moriyama, M., Ohnou, T., Godai, K., Kurimoto, T., Nakama, M., and Kanmura, Y. (2012). Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone attenuates postincisional pain by regulating macrophage polarization. Biochem. Biophys. Res. Commun. 426, 76-82. doi: 10.1016/j.bbrc.2012.08.039
45. Home, P. D., Pocock, S. J., Beck-Nielsen, H., Curtis, P. S., Gomis, R., Hanefeld, M., et al. (2009). Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373, 2125-2135. doi: 10.1016/S0140-6736(09)60953-3
46. Home, P. D., Pocock, S. J., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Jones, N. P., et al. (2007). Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N. Engl. J. Med. 357, 28-38. doi: 10.1056/NEJMoa073394
47. Hounoki, H., Sugiyama, E., Mohamed, S. G.-K., Shinoda, K., Taki, H., Abdel-Aziz, H. O., et al. (2008). Activation of peroxisome proliferator-activated receptor gamma inhibits TNF-alpha-mediated osteoclast differentiation in human peripheral monocytes in part via suppression of monocyte chemoattractant protein-1 expression. Bone 42, 765-774. doi: 10.1016/j.bone.2007.11.016
48. Huising, M. O., Stet, R. J. M., Kruiswijk, C. P., Savelkoul, H. F. J., and Lidy Verburg-van Kemenade, B. M. (2003). Molecular evolution of CXC chemokines: extant CXC chemokines originate from the CNS. Trends Immunol. 24, 307-313. doi: 10.1016/s1471-4906(03)00120-0
49. Imaizumi, T., Matsumiya, T., Tamo, W., Shibata, T., Fujimoto, K., Kumagai, M., et al. (2002). 15-Deoxy-D12, 14-prostaglandin J2 inhibits CX3CL1/fractalkine expression in human endothelial cells. Immunol. Cell Biol. 80, 531-536. doi: 10.1046/j.1440-1711.2002.01111.x
50. Impellizzeri, D., Esposito, E., Di Paola, R., Ahmad, A., Campolo, M., Peli, A., et al. (2013). Palmitoylethanolamide and luteolin ameliorate development of arthritis caused by injection of collagen type II in mice. Arthritis Res. Ther. 15: R192. doi: 10.1186/ar4382
51. Ito, H., Nakano, A., Kinoshita, M., and Matsumori, A. (2003). Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model. Lab. Invest. 83, 1715-1721. doi: 10.1097/01.lab.0000106724.29121.da
52. Jain, V., Jaggi, A. S., and Singh, N. (2009). Ameliorative potential of rosiglitazone in tibial and sural nerve transection-induced painful neuropathy in rats. Pharmacol. Res. 59, 385-392. doi: 10.1016/j.phrs.2009.02.001
53. Jia, H.-B., Wang, X.-M., Qiu, L.-L., Liu, X.-Y., Shen, J.-C., Ji, Q., et al. (2013). Spinal neuroimmune activation inhibited by repeated administration of pioglitazone in rats after L5 spinal nerve transection. Neurosci. Lett. 543, 130-135. doi: 10.1016/j.neulet.2013.03.046
54. Jiang, C., Ting, A. T., and Seed, B. (1998). PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391, 82-86. doi: 10.1038/34184
55. Jung, H., Toth, P. T., White, F. A., and Miller, R. J. (2008). Monocyte chemoattractant protein-1 functions as a neuromodulator in dorsal root ganglia neurons. J. Neurochem. 104, 254-263. doi: 10.1111/j.1471-4159.2007.04969.x
56. Kalliomäki, J., Attal, N., Jonzon, B., Bach, F. W., Huizar, K., Ratcliffe, S., et al. (2013). A randomized, double-blind, placebo-controlled trial of a chemokine receptor 2 (CCR2) antagonist in posttraumatic neuralgia. Pain 154, 761-767. doi: 10.1016/j.pain.2013.02.003
57. Keppel Hesselink, J. M. (2012). New targets in pain, non-neuronal cells and the role of Palmitoylethanolamide. Open Pain J. 5, 12-23. doi: 10.2174/1876386301205010012
58. Keppel Hesselink, J. M., and Hekker, T. A. (2012). Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series. J. Pain Res. 5, 437-442. doi: 10.2147/JPR.S32143
59. Khasabova, I. A., Xiong, Y., Coicou, L. G., Piomelli, D., and Seybold, V. (2012). Peroxisome proliferator-activated receptor α mediates acute effects of palmitoylethanolamide on sensory neurons. J. Neurosci. 32, 12735-12743. doi: 10.1523/JNEUROSCI.0130-12.2012
60. Kielian, T., McMahon, M., Bearden, E. D., Baldwin, A. C., Drew, P. D., and Esen, N. (2004). S. aureus-dependent microglial activation is selectively attenuated by the cyclopentenone prostaglandin 15-deoxy-Delta12, 14-prostaglandin J2 (15d-PGJ2). J. Neurochem. 90, 1163-1172. doi: 10.1111/j.1471-4159.2004.02579.x
61. Kiguchi, N., Kobayashi, Y., Maeda, T., Saika, F., and Kishioka, S. (2010a). CC-chemokine MIP-1α in the spinal cord contributes to nerve injury-induced neuropathic pain. Neurosci. Lett. 484, 17-21. doi: 10.1016/j.neulet.2010.07.085
62. Kiguchi, N., Maeda, T., Kobayashi, Y., Fukazawa, Y., and Kishioka, S. (2010b). Macrophage inflammatory protein-1alpha mediates the development of neuropathic pain following peripheral nerve injury through interleukin-1beta up-regulation. Pain 149, 305-315. doi: 10.1016/j.pain.2010.02.025
63. Kim, H. Y., and Kim, H. S. (2007). Upregulation of MIP-2 (CXCL2) expression by 15-deoxy-Delta(12, 14)-prostaglandin J(2) in mouse peritoneal macrophages. Immunol. Cell Biol. 85, 60-67. doi: 10.1038/sj.icb.7100001
64. Kim, S. E., Lee, E. O., Yang, J. H., Kang, J. H. L., Suh, Y.-H., and Chong, Y. H. (2012). 15-deoxy-delta12, 14-prostaglandin J2 inhibits human immunodeficiency virus-1 tat-induced monocyte chemoattractant protein-1/CCL2 production by blocking the extracellular signal-regulated kinase-1/2 signaling pathway independently of peroxisome proliferator-activated receptor-gamma and heme oxygenase-1 in rat hippocampal slices. J. Neurosci. Res. 90, 1732-1742. doi: 10.1002/jnr.23051
65. Kim, D., You, B., Lim, H., and Lee, S. J. (2011). Toll-like receptor 2 contributes to chemokine gene expression and macrophage infiltration in the dorsal root ganglia after peripheral nerve injury. Mol. Pain 7: 74. doi: 10.1186/1744-8069-7-74
66. Kintscher, U., Goetze, S., Wakino, S., Kim, S., Nagpal, S., Chandraratna, R. A., et al. (2000). Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes. Eur. J. Pharmacol. 401, 259-270. doi: 10.1016/s0014-2999(00)00461-1
67. Knerlich-Lukoschus, F., Juraschek, M., Blömer, U., Lucius, R., Mehdorn, H. M., and Held-Feindt, J. (2008). Force-dependent development of neuropathic central pain and time-related CCL2/CCR2 expression after graded spinal cord contusion injuries of the rat. J. Neurotrauma 25, 427-448. doi: 10.1089/neu.2007.0431
68. Knerlich-Lukoschus, F., Noack, M., von der Ropp-Brenner, B., Lucius, R., Mehdorn, H. M., and Held-Feindt, J. (2011a). Spinal cord injuries induce changes in CB1 cannabinoid receptor and C-C chemokine expression in brain areas underlying circuitry of chronic pain conditions. J. Neurotrauma 28, 619-634. doi: 10.1089/neu.2010.1652
69. Knerlich-Lukoschus, F., von der Ropp-Brenner, B., Lucius, R., Mehdorn, H. M., and Held-Feindt, J. (2011b). Spatiotemporal CCR1, CCL3(MIP-1α), CXCR4, CXCL12(SDF-1α) expression patterns in a rat spinal cord injury model of posttraumatic neuropathic pain. J. Neurosurg. Spine 14, 583-597. doi: 10.3171/2010.12.SPINE10480
70. Kopsky, D. J., and Keppel Hesselink, J. M. (2012). Multimodal stepped care approach with acupuncture and PPAR-α agonist palmitoylethanolamide in the treatment of a patient with multiple sclerosis and central neuropathic pain. Acupunct. Med. 30, 53-55. doi: 10.1136/acupmed-2011-010119
71. Koshiba, T., Hosotani, R., Miyamoto, Y., Ida, J., Tsuji, S., Nakajima, S., et al. (2000). Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin. Cancer Res. 6, 3530-3535.
72. Kuehl, F. A., Jacob, T. A., Ganley, O. H., Ormond, R. E., and Meisinger, M. A. P. (1957). The identification of N-(2-hydroxyethyl)-palmitamide as a naturally occurring anti-inflammatory agent. J. Am. Chem. Soc. 79, 5577-5578. doi: 10.1021/ja01577a066
73. Lee, C.-H., Chawla, A., Urbiztondo, N., Liao, D., Boisvert, W. A., Evans, R. M., et al. (2003). Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science 302, 453-457. doi: 10.1126/science.1087344
74. Lee, J. H., Kim, H., Woo, J. H., Joe, E., and Jou, I. (2012). 5, 8, 11, 14-eicosatetraynoic acid suppresses CCL2/MCP-1 expression in IFN-γ-stimulated astrocytes by increasing MAPK phosphatase-1 mRNA stability. J. Neuroinflammation 9: 34. doi: 10.1186/1742-2094-9-34
75. Lee, J. H., Woo, J. H., Woo, S. U., Kim, K. S., Park, S. M., Joe, E., et al. (2008). The 15-deoxy-delta 12, 14-prostaglandin J2 suppresses monocyte chemoattractant protein-1 expression in IFN-gamma-stimulated astrocytes through induction of MAPK phosphatase-1. J. Immunol. 181, 8642-8649. doi: 10.4049/jimmunol.181.12.8642
76. Li, Y., Douglas, S. D., Pleasure, D. E., Lai, J., Guo, C., Bannerman, P., et al. (2003). Human neuronal cells (NT2-N) express functional substance P and neurokinin-1 receptor coupled to MIP-1 beta expression. J. Neurosci. Res. 71, 559-566. doi: 10.1002/jnr.10504
77. Li, S., Gokden, N., Okusa, M. D., Bhatt, R., and Portilla, D. (2005). Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF. Am. J. Physiol. Renal Physiol. 289, F469-F480. doi: 10.1152/ajprenal.00038.2005
78. Lindia, J. A., McGowan, E., Jochnowitz, N., and Abbadie, C. (2005). Induction of CX3CL1 expression in astrocytes and CX3CR1 in microglia in the spinal cord of a rat model of neuropathic pain. J. Pain 6, 434-438. doi: 10.1016/j.jpain.2005.02.001
79. Liou, J.-T., Yuan, H.-B., Mao, C.-C., Lai, Y.-S., and Day, Y.-J. (2012). Absence of C-C motif chemokine ligand 5 in mice leads to decreased local macrophage recruitment and behavioral hypersensitivity in a murine neuropathic pain model. Pain 153, 1283-1291. doi: 10.1016/j.pain.2012.03.008
80. Liu, X., Yu, H., Yang, L., Li, C., and Li, L. (2012). 15-Deoxy-Δ(12, 14)-prostaglandin J(2) attenuates the biological activities of monocyte/macrophage cell lines. Eur. J. Cell Biol. 91, 654-661. doi: 10.1016/j.ejcb.2012.03.004
81. Loría, F., Petrosino, S., Mestre, L., Spagnolo, A., Correa, F., Hernangómez, M., et al. (2008). Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. Eur. J. Neurosci. 28, 633-641. doi: 10.1111/j.1460-9568.2008.06377.x
82. LoVerme, J., Russo, R., La Rana, G., Fu, J., Farthing, J., Mattace-Raso, G., et al. (2006). Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J. Pharmacol. Exp. Ther. 319, 1051-1061. doi: 10.1124/jpet.106.111385
83. Lu, M., Grove, E. A., and Miller, R. J. (2002). Abnormal development of the hippocampal dentate gyrus in mice lacking the CXCR4 chemokine receptor. Proc. Natl. Acad. Sci. U S A 99, 7090-7095. doi: 10.1073/pnas.092013799
84. Lu, Y., Zhou, Q., Zhong, F., Guo, S., Hao, X., Li, C., et al. (2013). 15-deoxy-Δ(12, 14)-prostaglandin J(2) modulates lipopolysaccharide-induced chemokine expression by blocking nuclear factor-κB activation via peroxisome proliferator activated receptor-γ-independent mechanism in renal tubular epithelial cells. Nephron Exp. Nephrol. 123, 1-10. doi: 10.1159/000353232
85. Maeda, T., Kiguchi, N., Kobayashi, Y., Ozaki, M., and Kishioka, S. (2008). Pioglitazone attenuates tactile allodynia and thermal hyperalgesia in mice subjected to peripheral nerve injury. J. Pharmacol. Sci. 108, 341-347. doi: 10.1254/jphs.08207fp
86. Malur, A., Mccoy, A. J., Arce, S., Barna, B. P., Kavuru, M. S., Malur, A. G., et al. (2009). Deletion of PPAR gamma in alveolar macrophages is associated with a Th-1 pulmonary inflammatory response. J. Immunol. 182, 5816-5822. doi: 10.4049/jimmunol.0803504
87. Marchesi, C., Rehman, A., Rautureau, Y., Kasal, D. A., Briet, M., Leibowitz, A., et al. (2013). Protective role of vascular smooth muscle cell PPAR gamma in angiotensin II-induced vascular disease. Cardiovasc. Res. 97, 562-570. doi: 10.1093/cvr/cvs362
88. Medzhitov, R. (2008). Origin and physiological roles of inflammation. Nature 454, 428-435. doi: 10.1038/nature07201
89. Milligan, E. D., Zapata, V., Chacur, M., Schoeniger, D., Biedenkapp, J., O'Connor, K. A., et al. (2004). Evidence that exogenous and endogenous fractalkine can induce spinal nociceptive facilitation in rats. Eur. J. Neurosci. 20, 2294-2302. doi: 10.1111/j.1460-9568.2004.03709.x
90. Mizutani, N., Sakurai, T., Shibata, T., Uchida, K., Fujita, J., Kawashima, R., et al. (2007). Dose-dependent differential regulation of cytokine secretion from macrophages by fractalkine. J. Immunol. 179, 7478-7487. doi: 10.4049/jimmunol.179.11.7478
91. Moalem, G., and Tracey, D. J. (2006). Immune and inflammatory mechanisms in neuropathic pain. Brain Res. Rev. 51, 240-264. doi: 10.1016/j.brainresrev.2005.11.004
92. Moreno, S., Farioli-Vecchioli, S., and Cerù, M. P. (2004). Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 123, 131-145. doi: 10.1016/j.neuroscience.2003.08.064
93. Morgenweck, J., Abdel-Aleem, O. S., McNamara, K. C., Donahue, R. R., Badr, M. Z., and Taylor, B. K. (2010). Activation of peroxisome proliferator-activated receptor gamma in brain inhibits inflammatory pain, dorsal horn expression of Fos and local edema. Neuropharmacology 58, 337-345. doi: 10.1016/j.neuropharm.2009.10.008
94. Morgenweck, J., Griggs, R. B., Donahue, R. R., Zadina, J. E., and Taylor, B. K. (2013). PPARγ activation blocks development and reduces established neuropathic pain in rats. Neuropharmacology 70, 236-246. doi: 10.1016/j.neuropharm.2013.01.020
95. Moulin, D. E. (1998). Pain in central and peripheral demyelinating disorders. Neurol. Clin. 16, 889-898. doi: 10.1016/s0733-8619(05)70103-1
96. Myers, R. R., Campana, W. M., and Shubayev, V. I. (2006). The role of neuroinflammation in neuropathic pain: mechanisms and therapeutic targets. Drug Discov. Today 11, 8-20. doi: 10.1016/s1359-6446(05)03637-8
97. Nandi, P. R. (2012). Pain in neurological conditions. Curr. Opin. Support. Palliat. Care 6, 194-200. doi: 10.1097/SPC.0b013e328352edff
98. Neri, T., Armani, C., Pegoli, A., Cordazzo, C., Carmazzi, Y., Brunelleschi, S., et al. (2011). Role of NF-kappaB and PPAR-gamma in lung inflammation induced by monocyte-derived microparticles. Eur. Respir. J. 37, 1494-1502. doi: 10.1183/09031936.00023310
99. Oh, S. B., Tran, P. B., Gillard, S. E., Hurley, R. W., Hammond, D. L., and Miller, R. J. (2001). Chemokines and glycoprotein120 produce pain hypersensitivity by directly exciting primary nociceptive neurons. J. Neurosci. 21, 5027-5035.
100. Onuta, G., Rienstra, H., de Boer, J. F., Boer, M. W., Roks, A. J. M., Klatter, F. A., et al. (2007). Rosiglitazone attenuates transplant arteriosclerosis after allogeneic aorta transplantation in rats. Transplantation 84, 517-526. doi: 10.1097/01.tp.0000276983.91892.99
101. Padi, S. S. V., Shi, X. Q., Zhao, Y. Q., Ruff, M. R., Baichoo, N., Pert, C. B., et al. (2012). Attenuation of rodent neuropathic pain by an orally active peptide, RAP-103, which potently blocks CCR2-and CCR5-mediated monocyte chemotaxis and inflammation. Pain 153, 95-106. doi: 10.1016/j.pain.2011.09.022
102. Park, H. J., and Moon, D. E. (2010). Pharmacologic management of chronic pain. Korean J. Pain. 23, 99-108. doi: 10.3344/kjp.2010.23.2.99
103. Park, S.-W., Yi, J.-H., Miranpuri, G., Satriotomo, I., Bowen, K., Resnick, D. K., et al. (2007). Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain and inflammation after spinal cord injury in adult rats. J. Pharmacol. Exp. Ther. 320, 1002-1012. doi: 10.1124/jpet.106.113472
104. Pascual, G., Fong, A. L., Ogawa, S., Gamliel, A., Li, A. C., Perissi, V., et al. (2005). A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 437, 759-763. doi: 10.1038/nature03988
105. Pascual, G., and Glass, C. K. (2006). Nuclear receptors versus inflammation: mechanisms of transrepression. Trends Endocrinol. Metab. 17, 321-327. doi: 10.1016/j.tem.2006.08.005
106. Paterniti, I., Impellizzeri, D., Crupi, R., Morabito, R., Campolo, M., Esposito, E., et al. (2013). Molecular evidence for the involvement of PPAR-δ and PPAR-γ in anti-inflammatory and neuroprotective activities of palmitoylethanolamide after spinal cord trauma. J. Neuroinflammation 10: 20. doi: 10.1186/1742-2094-10-20
107. Pease, J. E., and Horuk, R. (2009). Chemokine receptor antagonists: part 1. Expert. Opin. Ther. Pat. 19, 39-58. doi: 10.1517/13543770802641346
108. Pevida, M., Lastra, A., Hidalgo, A., Baamonde, A., and Menéndez, L. (2013). Spinal CCL2 and microglial activation are involved in paclitaxel-evoked cold hyperalgesia. Brain Res. Bull. 95, 21-27. doi: 10.1016/j.brainresbull.2013.03.005
109. Plunkett, J. A., Yu, C. G., Easton, J. M., Bethea, J. R., and Yezierski, R. P. (2001). Effects of interleukin-10 (IL-10) on pain behavior and gene expression following excitotoxic spinal cord injury in the rat. Exp. Neurol. 168, 144-154. doi: 10.1006/exnr.2000.7604
110. Pöllmann, W., and Feneberg, W. (2008). Current management of pain associated with multiple sclerosis. CNS Drugs22, 291-324. doi: 10.2165/00023210-200822040-00003
111. Pritts, E. A., Zhao, D., Ricke, E., Waite, L., and Taylor, R. N. (2002). PPAR-gamma decreases endometrial stromal cell transcription and translation of RANTES in vitro. J. Clin. Endocrinol. Metab. 87, 1841-1844. doi: 10.1210/jc.87.4.1841
112. Qin, X., Wan, Y., and Wang, X. (2005). CCL2 and CXCL1 trigger calcitonin gene-related peptide release by exciting primary nociceptive neurons. J. Neurosci. Res. 82, 51-62. doi: 10.1002/jnr.20612
113. Racke, M. K., Gocke, A. R., Muir, M., Diab, A., Drew, P. D., and Lovett-Racke, A. E. (2006). Nuclear receptors and autoimmune disease: the potential of PPAR agonists to treat multiple sclerosis. J. Nutr. 136, 700-703.
114. Rempel, S. A., Dudas, S., Ge, S., and Gutiérrez, J. A. (2000). Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. Clin. Cancer Res. 6, 102-111.
115. Richard, C. L., and Blay, J. (2008). CXCR4 in cancer and its regulation by PPARgamma. PPAR Res. 2008: 769413. doi: 10.1155/2008/769413
116. Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., and Glass, C. K. (1998). The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391, 79-82. doi: 10.1038/34178
117. Rival, Y., Benéteau, N., Taillandier, T., Pezet, M., Dupont-Passelaigue, E., Patoiseau, J. F., et al. (2002). PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells. Eur. J. Pharmacol. 435, 143-151. doi: 10.1016/s0014-2999(01)01589-8
118. Sacerdote, P., Franchi, S., Trovato, A. E., Valsecchi, A. E., Panerai, A. E., and Colleoni, M. (2008). Transient early expression of TNF-alpha in sciatic nerve and dorsal root ganglia in a mouse model of painful peripheral neuropathy. Neurosci. Lett. 436, 210-213. doi: 10.1016/j.neulet.2008.03.023
119. Sandhir, R., Gregory, E., He, Y.-Y., and Berman, N. E. J. (2011). Upregulation of inflammatory mediators in a model of chronic pain after spinal cord injury. Neurochem. Res. 36, 856-862. doi: 10.1007/s11064-011-0414-5
120. Sasso, O., Moreno-Sanz, G., Martucci, C., Realini, N., Dionisi, M., Mengatto, L., et al. (2013). Antinociceptive effects of the N-acylethanolamine acid amidase inhibitor ARN077 in rodent pain models. Pain 154, 350-360. doi: 10.1016/j.pain.2012.10.018
121. Sauter, M., Kastenmüller, K., Belling, F., Wörnle, M., Ladurner, R., Mussack, T., et al. (2012). Activation of peroxisome proliferator-activated receptor-gamma by glitazones reduces the expression and release of monocyte chemoattractant protein-1 in human mesothelial cells. Mediators Inflamm. 2012: 217696. doi: 10.1155/2012/217696
122. Savarin-Vuaillat, C., and Ransohoff, R. M. (2007). Chemokines and chemokine receptors in neurological disease: raise, retain, or reduce? Neurotherapeutics 4, 590-601. doi: 10.1016/j.nurt.2007.07.004
123. Schifilliti, C., Cucinotta, L., Fedele, V., Ingegnosi, C., Luca, S., and Leotta, C. (2014). Micronized Palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res. Treat. 2014: 849623. doi: 10.1155/2014/849623
124. Serrano, A., Paré, M., McIntosh, F., Elmes, S. J. R., Martino, G., Jomphe, C., et al. (2010). Blocking spinal CCR2 with AZ889 reversed hyperalgesia in a model of neuropathic pain. Mol. Pain 6: 90. doi: 10.1186/1744-8069-6-90
125. Skaper, S. D., Facci, L., Fusco, M., Della Valle, M. F., Zusso, M., Costa, B., et al. (2014). Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology 22, 79-94. doi: 10.1007/s10787-013-0191-7
126. Sommer, C., Galbraith, J. A., Heckman, H. M., and Myers, R. R. (1993). Pathology of experimental compression neuropathy producing hyperesthesia. J. Neuropathol. Exp. Neurol. 52, 223-233. doi: 10.1097/00005072-199305000-00006
127. Spiegelman, B. M. (1998). PPARγ in monocytes: less pain, any gain? Cell 93, 153-155. doi: 10.1016/S0092-8674(00)81567-6
128. Staniland, A. A., Clark, A. K., Wodarski, R., Sasso, O., Maione, F., D'Acquisto, F., et al. (2010). Reduced inflammatory and neuropathic pain and decreased spinal microglial response in fractalkine receptor (CX3CR1) knockout mice. J. Neurochem. 114, 1143-1157. doi: 10.1111/j.1471-4159.2010.06837.x
129. Storer, P. D., Xu, J., Chavis, J. A., and Drew, P. D. (2005a). Cyclopentenone prostaglandins PGA2 and 15-deoxy-delta12, 14 PGJ2 suppress activation of murine microglia and astrocytes: implications for multiple sclerosis. J. Neurosci. Res. 80, 66-74. doi: 10.1002/jnr.20413
130. Storer, P. D., Xu, J., Chavis, J., and Drew, P. D. (2005b). Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis. J. Neuroimmunol. 161, 113-122. doi: 10.1016/j.jneuroim.2004.12.015
131. Sun, J. H., Yang, B., Donnelly, D. F., Ma, C., and LaMotte, R. H. (2006). MCP-1 enhances excitability of nociceptive neurons in chronically compressed dorsal root ganglia. J. Neurophysiol. 96, 2189-2199. doi: 10.1152/jn.00222.2006
132. Szanto, A., and Nagy, L. (2008). The many faces of PPARgamma: anti-inflammatory by any means? Immunobiology 213, 789-803. doi: 10.1016/j.imbio.2008.07.015
133. Takahashi, Y., Hasegawa-Moriyama, M., Sakurai, T., and Inada, E. (2011). The macrophage-mediated effects of the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone attenuate tactile allodynia in the early phase of neuropathic pain development. Anesth. Analg. 113, 398-404. doi: 10.1213/ANE.0b013e31821b220c
134. Tan, N. S., Michalik, L., Desvergne, B., and Wahli, W. (2005). Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes. J. Steroid Biochem. Mol. Biol. 93, 99-105. doi: 10.1016/j.jsbmb.2004.12.025
135. Tanaka, T., Fukunaga, Y., Itoh, H., Doi, K., Yamashita, J., Chun, T.-H., et al. (2005). Therapeutic potential of thiazolidinediones in activation of peroxisome proliferator-activated receptor gamma for monocyte recruitment and endothelial regeneration. Eur. J. Pharmacol. 508, 255-265. doi: 10.1016/j.ejphar.2004.10.056
136. Taylor, B. K. (2013). N-acylethanolamine acid amidase (NAAA), a new path to unleash PPAR-mediated analgesia. Pain 154, 326-327. doi: 10.1016/j.pain.2012.12.012
137. Torrance, N., Smith, B. H., Bennett, M. I., and Lee, A. J. (2006). The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J. Pain 7, 281-289. doi: 10.1016/j.jpain.2005.11.008
138. Truini, A., Biasiotta, A., Di Stefano, G., La Cesa, S., Leone, C., Cartoni, C., et al. (2011). Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy. CNS Neurol. Disord. Drug Targets 10, 916-920. doi: 10.2174/187152711799219307
139. Tureyen, K., Kapadia, R., Bowen, K. K., Satriotomo, I., Liang, J., Feinstein, D. L., et al. (2007). Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J. Neurochem. 101, 41-56. doi: 10.1111/j.1471-4159.2006.04376.x
140. Uçeyler, N., Tscharke, A., and Sommer, C. (2007). Early cytokine expression in mouse sciatic nerve after chronic constriction nerve injury depends on calpain. Brain Behav. Immun. 21, 553-560. doi: 10.1016/j.bbi.2006.10.003
141. Ueno, T., Teraoka, N., Takasu, S., Nakano, K., Takahashi, M., Yamamoto, M., et al. (2012). Suppressive effect of pioglitazone, a PPAR gamma ligand, on azoxymethane-induced colon aberrant crypt foci in KK-A gamma mice. Asian Pac. J. Cancer Prev. 13, 4067-4073. doi: 10.7314/apjcp.2012.13.8.4067
142. Van Der Voorn, P., Tekstra, J., Beelen, R. H., Tensen, C. P., Van Der Valk, P., and De Groot, C. J. (1999). Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions. Am. J. Pathol. 154, 45-51. doi: 10.1016/s0002-9440(10)65249-2
143. van Neerven, S., and Mey, J. (2007). RAR/RXR and PPAR/RXR signaling in spinal cord injury. PPAR Res. 2007: 29275. doi: 10.1155/2007/29275
144. Van Steenwinckel, J., Reaux-Le Goazigo, A., Pommier, B., Mauborgne, A., Dansereau, M.-A., Kitabgi, P., et al. (2011). CCL2 released from neuronal synaptic vesicles in the spinal cord is a major mediator of local inflammation and pain after peripheral nerve injury. J. Neurosci. 31, 5865-5875. doi: 10.1523/JNEUROSCI.5986-10.2011
145. Verge, G. M., Milligan, E. D., Maier, S. F., Watkins, L. R., Naeve, G. S., and Foster, A. C. (2004). Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) distribution in spinal cord and dorsal root ganglia under basal and neuropathic pain conditions. Eur. J. Neurosci. 20, 1150-1160. doi: 10.1111/j.1460-9568.2004.03593.x
146. von Hehn, C. A., Baron, R., and Woolf, C. J. (2012). Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron 73, 638-652. doi: 10.1016/j.neuron.2012.02.008
147. Walcher, D., Hess, K., Heinz, P., Petscher, K., Vasic, D., Kintscher, U., et al. (2008). Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-gamma. Hypertension 51, 259-266. doi: 10.1161/hypertensionaha.107.099028
148. Wall, P. D., and Gutnick, M. (1974). Properties of afferent nerve impulses originating from a neuroma. Nature 248, 740-743. doi: 10.1038/248740a0
149. Wan, Y., and Evans, R. M. (2010). Rosiglitazone activation of PPARgamma suppresses fractalkine signaling. J. Mol. Endocrinol. 44, 135-142. doi: 10.1677/JME-09-0090
150. Wang, W. M., Chen, H., Zhong, F., Lu, Y., Han, L., and Chen, N. (2011). Inhibitory effects of rosiglitazone on lipopolysaccharide-induced inflammation in a murine model and HK-2 cells. Am. J. Nephrol. 34, 152-162. doi: 10.1159/000329120
151. Wang, H., Jiang, R., He, Q., Zhang, Y., Zhang, Y., Li, Y., et al. (2012). Expression pattern of peroxisome proliferator-activated receptors in rat hippocampus following cerebral ischemia and reperfusion injury. PPAR Res. 2012: 596394. doi: 10.1155/2012/596394
152. Welch, J. S., Ricote, M., Akiyama, T. E., Gonzalez, F. J., and Glass, C. K. (2003). PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc. Natl. Acad. Sci. U S A 100, 6712-6717. doi: 10.1073/pnas.1031789100
153. Wen, X., Li, Y., and Liu, Y. (2010). Opposite action of peroxisome proliferator-activated receptor-gamma in regulating renal inflammation: functional switch by its ligand. J. Biol. Chem. 285, 29981-29988. doi: 10.1074/jbc.M110.110908
154. Werhagen, L., Budh, C. N., Hultling, C., and Molander, C. (2004). Neuropathic pain after traumatic spinal cord injury-relations to gender, spinal level, completeness and age at the time of injury. Spinal Cord 42, 665-673. doi: 10.1038/sj.sc.3101641
155. White, F. A., Bhangoo, S. K., and Miller, R. J. (2005a). Chemokines: integrators of pain and inflammation. Nat. Rev. Drug Discov. 4, 834-844. doi: 10.1038/nrd1852
156. White, F. A., Sun, J., Waters, S. M., Ma, C., Ren, D., Ripsch, M., et al. (2005b). Excitatory monocyte chemoattractant protein-1 signaling is up-regulated in sensory neurons after chronic compression of the dorsal root ganglion. Proc. Natl. Acad. Sci. U S A 102, 14092-14097. doi: 10.1073/pnas.0503496102
157. Wilson, N. M., Jung, H., Ripsch, M. S., Miller, R. J., and White, F. A. (2011). CXCR4 signaling mediates morphine-induced tactile hyperalgesia. Brain Behav. Immun. 25, 565-573. doi: 10.1016/j.bbi.2010.12.014
158. Woolf, C. J., and Mannion, R. J. (1999). Neuropathic pain: aetiology, symptoms, mechanisms and management. Lancet 353, 1959-1964. doi: 10.1016/s0140-6736(99)01307-0
159. Wu, G., Ringkamp, M., Murinson, B. B., Pogatzki, E. M., Hartke, T. V., Weerahandi, H. M., et al. (2002). Degeneration of myelinated efferent fibers induces spontaneous activity in uninjured C-fiber afferents. J. Neurosci. 22, 7746-7753.
160. Xiao, Y., Xu, J., Wang, S., Mao, C., Jin, M., Ning, G., et al. (2010). Genetic ablation of steroid receptor coactivator-3 promotes PPAR-beta-mediated alternative activation of microglia in experimental autoimmune encephalomyelitis. Glia 58, 932-942. doi: 10.1002/glia.20975
161. Xu, J., Storer, P. D., Chavis, J. A., Racke, M. K., and Drew, P. D. (2005). Agonists for the peroxisome proliferator-activated receptor-alpha and the retinoid X receptor inhibit inflammatory responses of microglia. J. Neurosci. Res. 81, 403-411. doi: 10.1002/jnr.20518
162. Yan, Y.-P., Sailor, K. A., Lang, B. T., Park, S.-W., Vemuganti, R., and Dempsey, R. J. (2007). Monocyte chemoattractant protein-1 plays a critical role in neuroblast migration after focal cerebral ischemia. J. Cereb. Blood Flow Metab. 27, 1213-1224. doi: 10.1038/sj.jcbfm.9600432
163. Yang, J.-L., Xu, B., Li, S.-S., Zhang, W.-S., Xu, H., Deng, X.-M., et al. (2012). Gabapentin reduces CX3CL1 signaling and blocks spinal microglial activation in monoarthritic rats. Mol. Brain 5: 18. doi: 10.1186/1756-6606-5-18
164. Yi, J.-H., Park, S.-W., Brooks, N., Lang, B. T., and Vemuganti, R. (2008). PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms. Brain Res. 1244, 164-172. doi: 10.1016/j.brainres.2008.09.074
165. Yoshimura, T., Matsushima, K., Tanaka, S., Robinson, E. A., Appella, E., Oppenheim, J. J., et al. (1987). Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc. Natl. Acad. Sci. U S A 84, 9233-9237. doi: 10.1073/pnas.84.24.9233
166. Zelenka, M., Schäfers, M., and Sommer, C. (2005). Intraneural injection of interleukin-1beta and tumor necrosis factor-alpha into rat sciatic nerve at physiological doses induces signs of neuropathic pain. Pain 116, 257-263. doi: 10.1016/j.pain.2005.04.018
167. Zhang, J., and De Koninck, Y. (2006). Spatial and temporal relationship between monocyte chemoattractant protein-1 expression and spinal glial activation following peripheral nerve injury. J. Neurochem. 97, 772-783. doi: 10.1111/j.1471-4159.2006.03746.x
168. Zhang, Z.-J., Dong, Y.-L., Lu, Y., Cao, S., Zhao, Z.-Q., and Gao, Y.-J. (2012). Chemokine CCL2 and its receptor CCR2 in the medullary dorsal horn are involved in trigeminal neuropathic pain. J. Neuroinflammation 9: 136. doi: 10.1186/1742-2094-9-136
169. Zhang, N., Inan, S., Cowan, A., Sun, R., Wang, J. M., Rogers, T. J., et al. (2005). A proinflammatory chemokine, CCL3, sensitizes the heat-and capsaicin-gated ion channel TRPV1. Proc. Natl. Acad. Sci. U S A 102, 4536-4541. doi: 10.1073/pnas.0406030102
170. Zhang, J., Shi, X. Q., Echeverry, S., Mogil, J. S., De Koninck, Y., and Rivest, S. (2007). Expression of CCR2 in both resident and bone marrow-derived microglia plays a critical role in neuropathic pain. J. Neurosci. 27, 12396-12406. doi: 10.1523/jneurosci.3016-07.2007
171. Zhang, Y. J., Yang, X., Kong, Q. Y., Zhang, Y. F., Chen, W. Y., Dong, X. Q., et al. (2006). Effect of 15d-PGJ2 on the expression of CD40 and RANTES induced by IFN-gamma and TNF-alpha on renal tubular epithelial cells (HK-2). Am. J. Nephrol. 26, 356-362. doi: 10.1159/000094735
172. Zhao, Y., Patzer, A., Gohlke, P., Herdegen, T., and Culman, J. (2005). The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain. Eur. J. Neurosci. 22, 278-282. doi: 10.1111/j.1460-9568.2005.04200.x
173. Zhuang, Z.-Y., Kawasaki, Y., Tan, P.-H., Wen, Y.-R., Huang, J., and Ji, R.-R. (2007). Role of the CX3CR1/p38 MAPK pathway in spinal microglia for the development of neuropathic pain following nerve injury-induced cleavage of fractalkine. Brain Behav. Immun. 21, 642-651. doi: 10.1016/j.bbi.2006.11.003